Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IDEC-131. IDEC/Eisai.

Francis J Dumont1

  • 1Merck Research Laboratories, Department of Immunology, Rahway, NJ 07065, USA. francis_dumont@merck.com

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel pharmacological modulators of autophagy and therapeutic prospects.

Expert opinion on therapeutic patents·2012
Same author

Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.

Current cancer drug targets·2012
Same author

Cytokines: the magic is still there.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fontolizumab Protein Design Labs.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fingolimod. Mitsubishi Pharma/Novartis.

IDrugs : the investigational drugs journal·2005
Same author

Technology evaluation: abatacept, Bristol-Myers Squibb.

Current opinion in molecular therapeutics·2004
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

IDEC-131, an anti-CD154 monoclonal antibody, is being investigated for autoimmune diseases like psoriasis and Crohn's disease. Clinical trials are ongoing, with potential launch predicted for 2005.

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • IDEC-131 (E6040) is a humanized monoclonal antibody targeting CD154 (CD40L).
  • It is developed for autoimmune diseases, leveraging technology from Dartmouth Medical School demonstrating efficacy in animal models.
  • Previous development for systemic lupus erythematosus (SLE) was halted due to disappointing Phase II results.

Purpose of the Study:

  • To evaluate the safety and efficacy of IDEC-131 in treating autoimmune conditions.
  • To advance the development of IDEC-131 through various clinical trial phases.

Main Methods:

  • Phase I and Phase II clinical trials were initiated for psoriasis, idiopathic thrombocytopenic purpura (ITP), and Crohn's disease.
  • A pilot, multicenter, multiple-dose Phase I trial in moderate-to-severe psoriasis began in January 2001.

Related Experiment Videos

  • Phase I trials in multiple sclerosis were initiated by March 1999.

    • Main Results:

    • Phase II trials for psoriasis and ITP were initiated in January 2001.
    • A Phase II trial for Crohn's disease was ongoing by January 2002.
    • The Phase I trial for psoriasis was ongoing as of January 2002.

    Conclusions:

    • IDEC-131 is under active clinical investigation for multiple autoimmune diseases.
    • Despite setbacks in SLE, ongoing trials suggest continued development interest.
    • Analysts project a 2005 launch with significant sales potential.